Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

There's nothing like free publicity to help goose the sales of a relatively new product....

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

There's nothing like free publicity to help goose the sales of a relatively new product....

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

There's nothing like free publicity to help goose the sales of a relatively new product....

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

There's nothing like free publicity to help goose the sales of a relatively new product....

Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

There's nothing like free publicity to help goose the sales of a relatively new product....

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...